| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/22/2010 | CA2374346C Inhibitors of memapsin 2 and use thereof |
| 06/22/2010 | CA2331086C Hepatitis vaccine |
| 06/22/2010 | CA2256483C P13 lipid kinase |
| 06/22/2010 | CA2242878C Induction of immune response against desired determinants |
| 06/22/2010 | CA2216963C Tie-2 ligands, methods of making and uses thereof |
| 06/22/2010 | CA2175893C Protein tyrosine kinases named rse |
| 06/22/2010 | CA2122745C Bifunctional glycoproteins having a modified carbohydrate complement, and their use in tumor-selective therapy |
| 06/17/2010 | WO2010068923A2 Agents that selectively inhibit cd25 on dendritic cells or t cells and their use |
| 06/17/2010 | WO2010068705A2 Encapsulated agent guided imaging and therapies |
| 06/17/2010 | WO2010068680A1 Thelper cell type 17 lineage-specific adjuvants, compositions and methods |
| 06/17/2010 | WO2010068647A1 Vaccine for the prevention of breast cancer recurrence |
| 06/17/2010 | WO2010068437A1 Isoform specific anti-her4 antibodies |
| 06/17/2010 | WO2010068413A1 Chlamydia vaccine comprising htra polypeptides |
| 06/17/2010 | WO2010068310A1 Compositions, devices, kits and methods for detecting hookworm |
| 06/17/2010 | WO2010068308A1 Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease |
| 06/17/2010 | WO2010067671A1 Immunological reconstitution promoter or prophylactic agent for infections each of which maintains graft-versus-tumor effect |
| 06/17/2010 | WO2010067318A1 Compound, medicament, vaccine composition and nanocapsules |
| 06/17/2010 | WO2010067286A2 IgE CH3 PEPTIDE VACCINE |
| 06/17/2010 | WO2010067262A1 Immunostimulatory oligonucleotides |
| 06/17/2010 | WO2010067202A2 Mixing lyophilised meningococcal vaccines with non-hib vaccines |
| 06/17/2010 | WO2010067201A2 MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES |
| 06/17/2010 | WO2010066914A2 Remedies for pemphigus containing anti fas ligand antibodies |
| 06/17/2010 | WO2010066872A1 A monoclonal antibody and its use for the identification of the oncofetal isoform of fibronectin (b-fn) for diagnosis or therapy |
| 06/17/2010 | WO2010066868A2 Anti-igf antibodies |
| 06/17/2010 | WO2010066762A1 Antibody formulation |
| 06/17/2010 | WO2010066689A2 Organic compounds |
| 06/17/2010 | WO2010066634A1 Method for obtaining an excipient-free antibody solution |
| 06/17/2010 | WO2010066418A1 Use of flt3 ligand for strengthening immune responses in rna immunization |
| 06/17/2010 | WO2010066049A1 Methods and systems for inducing immunologic tolerance to non-self antigens |
| 06/17/2010 | WO2010066018A1 Novel human endogenous retorviral erv3 variant and uses thereof for diagnosing ovarian cancer |
| 06/17/2010 | WO2010065995A1 Isolated vegf-c and vegf-d peptides and uses thereof |
| 06/17/2010 | WO2010044919A3 Smallpox dna vaccine and the antigens therein that elicit an immune response |
| 06/17/2010 | WO2010033279A3 Antibodies with altered binding to fcrn and methods of using same |
| 06/17/2010 | WO2010027458A3 Pdk inhibitor compounds and methods of use thereof |
| 06/17/2010 | WO2010025050A3 Affecting bone related conditions using cd68 blocking agents |
| 06/17/2010 | WO2010021516A3 Novel use of lipocalin 2 for treating brain damage |
| 06/17/2010 | WO2010019570A3 Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof |
| 06/17/2010 | WO2010019565A3 Anti-ephrin b2 antibodies and their use in treatment of disease |
| 06/17/2010 | WO2009156960A3 Novel adjuvant compositions |
| 06/17/2010 | US20100154071 Fxdy5 modulators for treating, diagnosing, and detecting cancer |
| 06/17/2010 | US20100152110 Alternate reading frame polypeptides derived from hepatitis c and methods of their use |
| 06/17/2010 | US20100152095 Wound healing |
| 06/17/2010 | US20100151589 Glycoproteins Having Lipid Mobilising Properties and Therapeutic Applications Thereof |
| 06/17/2010 | US20100151466 Diagnosis and treatment of cervical cancer |
| 06/17/2010 | US20100151031 Discrete size and shape specific organic nanoparticles designed to elicit an immune response |
| 06/17/2010 | US20100151024 Therapeutic agent for ulcerative colitis |
| 06/17/2010 | US20100151010 Medicament in a multilayer form |
| 06/17/2010 | US20100151009 Formulations for delivering insulin |
| 06/17/2010 | US20100151000 Compositions and methods for modulating immune responses |
| 06/17/2010 | US20100150999 Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response |
| 06/17/2010 | US20100150998 Vaccines for malaria |
| 06/17/2010 | US20100150994 Amphiphilic entity nanoparticles |
| 06/17/2010 | US20100150969 immune response |
| 06/17/2010 | US20100150968 Dna vectors |
| 06/17/2010 | US20100150967 Treatment or prophylaxis of asthma |
| 06/17/2010 | US20100150966 Method for the diagnosis of tuberculosis |
| 06/17/2010 | US20100150965 Dna promoters and anthrax vaccines |
| 06/17/2010 | US20100150964 Polypeptides and methods for the specific detection of antibodies in patients with a borrelia infection |
| 06/17/2010 | US20100150963 Yeast-Based Therapeutic for Chronic Hepatitis C Infection |
| 06/17/2010 | US20100150962 Polypeptide fragments of the hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits |
| 06/17/2010 | US20100150961 Virus like particle purification |
| 06/17/2010 | US20100150960 Compositions and methods for chitosan enhanced immune response |
| 06/17/2010 | US20100150959 PCV 2-Based Methods and Compositions for the Treatment of Pigs |
| 06/17/2010 | US20100150958 Methods and Compositions for Use of a Coccidiosis Vaccine |
| 06/17/2010 | US20100150957 Peptides for active anti-cytokine immunization |
| 06/17/2010 | US20100150956 Multicomponent vaccines |
| 06/17/2010 | US20100150954 Vaccines against influenza virus |
| 06/17/2010 | US20100150953 Ii-KEY/HER-2/NEU HYBRID CANCER VACCINE |
| 06/17/2010 | US20100150952 pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY |
| 06/17/2010 | US20100150951 Plasmodium falciparum antigens inducing protective antibodies |
| 06/17/2010 | US20100150950 Human antibodies that bind cd70 and uses thereof |
| 06/17/2010 | US20100150949 Methods and compositions for modulating proline levels |
| 06/17/2010 | US20100150948 Materials and methods for improved immunoglycoproteins |
| 06/17/2010 | US20100150947 Tolerance induction and maintenance in hematopoietic stem cell allografts |
| 06/17/2010 | US20100150946 Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer |
| 06/17/2010 | US20100150945 Anti-mdl-1 antibodies |
| 06/17/2010 | US20100150944 Methods and compositions for diagnosis and treatment of depression and anxiety |
| 06/17/2010 | US20100150943 Immunogenic compositions for gram positive bacteria |
| 06/17/2010 | US20100150942 Affinity purified human polyclonal antibodies and methods of making and using them |
| 06/17/2010 | US20100150941 Hemagglutinin antibody and uses thereof |
| 06/17/2010 | US20100150940 Anti-igf antibodies |
| 06/17/2010 | US20100150939 Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders |
| 06/17/2010 | US20100150938 Methods and compositions for reducing inflammation and treating inflammatory disorders |
| 06/17/2010 | US20100150937 Antagonists of pcsk9 |
| 06/17/2010 | US20100150936 Prevention of rash in patients undergoing anti-egfr therapy |
| 06/17/2010 | US20100150935 Use of an anti-cxcr4 antibody in the treatment of cancer |
| 06/17/2010 | US20100150934 Botulinum antitoxin compositions and methods |
| 06/17/2010 | US20100150933 Cytokine antagonists for neurological and neuropsychiatric disorders |
| 06/17/2010 | US20100150932 Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics |
| 06/17/2010 | US20100150931 Novel receptor for cd40l and uses thereof |
| 06/17/2010 | US20100150930 Mage-11 as a marker for endometrial receptivity to embryo transplantation and a marker and therapeutic target in castration-recurrent prostate cancer |
| 06/17/2010 | US20100150929 Peptide Associated with Rheumatic Fever (PARF) and Its Use as a Diagnostic Marker |
| 06/17/2010 | US20100150928 Methods and compositions relating to zpa polypeptides |
| 06/17/2010 | US20100150927 Cell death inducer |
| 06/17/2010 | US20100150926 Fusion protein capable of binding vegf-a and tnf-alpha |
| 06/17/2010 | US20100150925 Treatment of b-cell cancers with anti-cd70 antibody-drug conjugates |
| 06/17/2010 | US20100150924 Regulation of myelination by nectin-like (necl) molecules |
| 06/17/2010 | US20100150923 Fusion proteins of recombinant sars coronavirus structural proteins, their production and uses |
| 06/17/2010 | US20100150922 Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus Pulposus |
| 06/17/2010 | US20100150921 KID31 And Antibodies That Bind Thereto |